Exelixis Inc. (0IJO)
LSE
Closed
Sep 28, 2026
Day's Range
57.0052 wk Range
33.81Overview - 0IJO - Exelixis Inc.
Key Statistics
Valuation
Enterprise Value
13.77B
P/E (Trailing)
‪0.63‬
Price / Book
‪7.86‬
EV / EBITDA
‪13.49‬
Profitability
Profit Margin
‪35.33%‬
Operating Margin
‪39.51%‬
Return on Assets
‪23.97%‬
Return on Equity
‪44.39%‬
Ownership
Shares Outstanding
298.98M
Float
213.60M
Held by Insiders
‪1.84%‬
Held by Institutions
‪106.76%‬
Price stats
Beta
‪0.42‬
50-Day Avg
‪21.98‬
200-Day Avg
‪21.24‬
Market Cap - 0IJO - Exelixis Inc.
Peers - 0IJO - Exelixis Inc.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0IJOLSEExelixis Inc.17.43BMarket Cap+31.27%52-week change0.63P/E (Trailing)‪35.33%‬Profit Margin
- 0MGBLSEGenmab A/S198.39BMarket Cap+15.12%52-week change33.69P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated Common Stock128.96BMarket Cap+20.00%52-week change0.53P/E (Trailing)‪34.99%‬Profit Margin
- 0A45LSEModerna Inc.95.05BMarket Cap+87.31%52-week change72.95P/E (Trailing)‪11.32%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.79.08BMarket Cap+20.99%52-week change0.11P/E (Trailing)‪27.86%‬Profit Margin
- 0QW0LSEargenx SE49.68BMarket Cap+27.60%52-week change40.07P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA41.70BMarket Cap-23.88%52-week change120.47P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0IJO - Exelixis Inc.
About
Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers. The company’s current portfolio centers on cancer therapies built around cabozantinib, including CABOMETYX and COMETRIQ, which are used across multiple tumor types in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
